Xeris Biopharma (XERS) Q1 2026 earnings review
Recorlev Hyper-Growth Drives Profitability, But Gvoke Flatlines
Xeris Biopharma delivered a strong start to 2026, posting its first Q1 net income ($2.2M) and raising the bottom end of its full-year revenue guidance. The story, however, is becoming entirely singular: Recorlev. The Cushing's syndrome therapy rocketed 95% YoY to $49.8M, single-handedly pulling total revenues up 38%. Conversely, legacy product Gvoke unexpectedly stalled, posting 0% YoY growth and casting doubt on management's prior claims of it being a 'steady, reliable' contributor. With SG&A spiking 21% to fund the newly expanded commercial team and looming Phase 3 R&D costs for XP-8121, execution on Recorlev is more critical than ever.
🐂 Bull Case
Recorlev nearly doubled YoY to $49.8M. The company just completed its commercial team expansion in Q1, meaning the heavy investments should drive even greater prescriber awareness and volume in the second half of 2026.
Gross margin expanded to 87% (from 85% a year ago) due to the higher-margin mix of Recorlev. This operating leverage translated to $15.1M in Adjusted EBITDA, completely self-funding the pipeline.
🐻 Bear Case
After posting 14% growth in FY25, Gvoke revenue dropped 15% sequentially and was completely flat YoY at $20.8M. The 'durable foundation' narrative is fracturing.
With Gvoke and Keveyis stagnating, Xeris is almost entirely dependent on Recorlev. With outstanding ANDA patent litigation filed in late 2025, any legal setback would cripple the company's valuation.
⚖️ Verdict: ⚪
Cautiously Bullish. Recorlev's momentum is undeniable and the pivot to net income is a major derisking milestone. However, the unexpected stall in Gvoke creates a concerning dependency on a single drug while operating expenses are ramping up.
Key Themes
Recorlev is the Undisputed Growth Engine
Recorlev sales accelerated, generating $49.8M (+95% YoY) and representing 60% of total product revenue, up from 44% a year ago. Management completed a targeted expansion of the commercial team this quarter. Given that new reps typically require a few quarters to reach optimal productivity, this implies sequential growth could accelerate further in late 2026.
Gvoke Growth Reverses Course
A major red flag emerged in the Gvoke franchise. Management spent 2025 praising it for 'steady, reliable growth' (+14% in FY25, +26% in 25Q1). In 26Q1, growth abruptly decelerated to 0% YoY ($20.8M) and fell sequentially from $24.6M in 25Q4. This starkly contradicts the positive narrative and suggests intense competitive or formulary pressures in the ready-to-use glucagon market.
Exceptional Operating Leverage
The margin profile is accelerating. Gross margin improved from 85% to 87%, primarily driven by the favorable product mix (Recorlev commands significantly higher margins). This allowed the company to absorb a $9.1M increase in SG&A while still flipping from a $9.2M net loss in 25Q1 to a $2.2M net profit in 26Q1.
Escalating Expense Base Requires Flawless Execution
SG&A expenses jumped 21% YoY to $53.1M, reflecting the commercial enterprise expansion. Additionally, R&D increased 13% to $8.8M. Management's FY26 blueprint calls for ~$45M in incremental SG&A and ~$25M in incremental R&D. If Recorlev growth stumbles, these fixed costs will quickly erase the newfound profitability.
XP-8121 Pipeline Advancement
XP-8121, a Phase 3-ready once-weekly subcutaneous injection for hypothyroidism, represents the primary pipeline catalyst for 2026. Targeting 3 to 5 million patients with GI absorption issues, management is prepping for a Phase 3 initiation later this year, which they label a 'significant value creation inflection point.'
Patent Litigation Overhang
While not explicitly updated in the Q1 release, the legacy Q4 narrative included Xeris filing a patent infringement lawsuit against two ANDA filers for Recorlev. With Recorlev now comprising the vast majority of the company's growth and value, this multi-year legal process remains a critical structural risk.
Other KPIs
Accelerating significantly from $4.4 million in 25Q1. This marks a $10.7M YoY improvement and demonstrates that the core business is highly cash-generative, safely funding the aggressive R&D step-up required for XP-8121 without needing dilutive capital.
Stable. Grew 4% YoY. This ultra-rare disease product continues to operate as a reliable cash cow, holding steady between $11M and $12.8M for the last five quarters.
Guidance
Accelerating. The bottom end was raised from previous implicit guidance of $375 million. The midpoint ($385M) implies robust 32% YoY growth compared to FY25's $291.8M. However, achieving this is highly dependent on Recorlev carrying the load, given Gvoke's weakness.
Key Questions
Gvoke Stagnation
Gvoke revenue was flat YoY and declined sequentially. Given your previous commentary about 'steady, reliable growth', is this driven by competitor formulary positioning, pricing pressure, or a plateau in underlying prescription volume?
Recorlev Sales Force Productivity
With the commercial expansion successfully completed in Q1, how long is the anticipated ramp to peak productivity for the new reps, and what specific leading indicators are you seeing from these new territories?
XP-8121 Clinical Timeline
Regarding the Phase 3 initiation for XP-8121 later this year, have all manufacturing scale-up and device verification gating items been fully resolved, or do regulatory hurdles remain before dosing the first patient?